Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus Biosciences — Diluted EPS by Year
Arcus Biosciences — Diluted EPS ($/sh) ($)
Gilead Sciences Arcus Biosciences — Diluted EPS: -$3.29 in FY2025, up 4.8% from a year earlier.
Latest, FY2025
-3.29
Period ended Dec 31, 2025
Change on a year earlier
+4.8%
-3.14 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Diluted EPS ($/sh) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.29 | +4.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2024 | Dec 31, 2024 | -3.14 | -24.3% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | -4.15 | +11.9% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2022 | Dec 31, 2022 | -3.71 | -622.5% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 0.71 | -131.7% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | -2.24 | +16.1% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | -1.93 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences — Diluted EPS ($), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-eps-diluted
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.